AzTrials
AzTrials

Gastric VaricesNCT02330731

N-butyl-2-cyanoacrylate, Iso-amyl-2-cyanoacrylate and Hypertonic Glucose With 72% Chromated Glycerin in Gastric Varices

A study testing injection sclerotherapy for gastric varices in people with Gastric Varices, run by Ain Shams University.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

AIM: To compare between n-butyl-2-cyanoacrylate, iso-amyl-2-cyanoacrylate and mixture of 72% chromated glycerin with hypertonic glucose solution in management of gastric varices. METHODS: Ninety patients with gastric varices presented to Endoscopy Unit of Ain Shams University Hospital were included. Read more about this study

Who is it for?
Ages 25 to 60 years
Conditions the study is for
Gastric Varices
What is being tested?
injection sclerotherapy for gastric varices
Could I receive a placebo?
No, everyone receives an active treatment
How many people
90 participants
Where
No sites listed yet
Study dates
Jan 2012to Oct 2012
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Patients with gastric varices presented to Endoscopy Unit of Ain Shams University Hospital

Who cannot join

  • Patients with non-variceal causes for upper GIT bleeding and those with severe co-morbidity

About this study

AIM: To compare between n-butyl-2-cyanoacrylate, iso-amyl-2-cyanoacrylate and mixture of 72% chromated glycerin with hypertonic glucose solution in management of gastric varices.

METHODS: Ninety patients with gastric varices presented to Endoscopy Unit of Ain Shams University Hospital were included. They were randomly allocated into three groups; each group included 30 patients treated with intravariceal sclerosant injections in biweekly sessions till complete obturation of gastric varices; Group I (n-butyl-2-cyanoacrylate; Histoacryl®), Group II (iso-amyl-2-cyanoacrylate; Amcrylate®) and Group III (mixture of 72% chromated glycerin; Scleremo® with glucose solution 25%). All the procedures were done electively without active bleeding. Recruited patients were followed up for 3 months.

Read the detailed description
  • Study Design \& Sampling: This prospective randomized study is conducted on ninety patients with gastric varices presented to Endoscopy Unit of Ain Shams University Hospital. Patients with non-variceal causes for upper GIT bleeding and those with severe co-morbidity are excluded.

Patients are randomly allocated into three groups; each group includes 30 patients who will be treated with sclerosant injections in biweekly sessions till complete obturation of gastric varices, with follow up for 3 months:

  • Group I (Histoacryl® Group),
  • Group II (Amcrylate® Group) and
  • Group III (Scleremo® with Glucose 25% Group). The three groups are matching as regards age, gender, cause of liver cirrhosis (viral hepatitis B or C), Child score and endoscopic findings (including number, grade of EV and size of GV).
  • Tools of the study:

All included patients will be subjected to:

  1. Complete clinical evaluation.
  2. Laboratory investigations: CBC, liver profile, viral markers (HBs Ag, HB core Ab, HCV Ab) by ELISA technique.
  3. Child classification according to the modified Child Pugh's criteria [13].
  4. Abdominal ultrasonography: liver and spleen size, portal vein diameter and ascites.
  5. Upper gastrointestinal endoscopy: using Pentax video endoscope EG 3440. Esophageal varices are classified according to their size at the gastroesophageal junction into 4 grades according to Westaby et al. [14]. Gastric varices are classified into: gastro-esophageal varices (GEV) and isolated gastric varices (IGV) according to Sarin et al. [15].
  6. Therapeutic interventions:

The intravariceal technique of injection is done according to Soehendra et al. [16].

Histoacryl® is diluted as 0.5 ml histoacryl: 0.8 ml lipidol as a contrast agent to dilute the adhesive material to fill the whole varix and to prevent rapid hardening and obstruction of the needle. The mixture is injected slowly to minimize the risk of embolization followed by injection of 2 ml of distilled water. The first ml of water is injected to push the material into the varix and the second ml is injected during withdrawal of the needle to prevent its obstruction [8].

Amcrylate® is injected slowly followed by injection of 2 ml distilled water without mixing with any other substances [17].

Scleremo® is mixed with glucose 25% in a ratio of 1:1. The mixture is injected very slowly and with the waiting for moments inside the variceal lumen after injection to give enough time for the sclerosing material to be in contact with the vessel wall that helps haemostasis. There is no need for distilled water injection [11].

Informed consent was obtained from all included patients and the study protocol was approved from the ethical guidelines committee.

All the procedures are done electively without active bleeding. The primary end point of this study is the obturation of gastric varices. The secondary endpoint is the occurrence of bleeding whether from the puncture site during or immediately after injection or delayed (in-hospital or after discharge) and mortality.

Conditions
Gastric Varices
Being tested
injection sclerotherapy for gastric varices
Medical subject headings
Esophageal and Gastric Varices

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • injection sclerotherapy for gastric varicesProcedure or surgery

    The intravariceal technique of injection

Study groups in NCT02330731
Study groupRoleWhat they receive
N-butyl-2-cyanoacrylateOtherinjection sclerotherapy for gastric varices
Receives: Procedure: injection sclerotherapy for gastric varices
iso-amyl-2-cyanoacrylateOtherinjection sclerotherapy for gastric varices
Receives: Procedure: injection sclerotherapy for gastric varices
72% chromated glycerinOtherinjection sclerotherapy for gastric varices
Receives: Procedure: injection sclerotherapy for gastric varices

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. obturation of gastric varices

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jan 2015 (estimated)
  2. Study startJan 2012
  3. Primary completionJun 2012
  4. Study completionOct 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
90 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02330731
Sponsor's protocol ID
482
Status last verified
Jan 2015
First submitted
1 Jan 2015
Last updated
5 Jan 2015
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing injection sclerotherapy for gastric varices in people with Gastric Varices, run by Ain Shams University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Jan 2015. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

obturation of gastric varices (time frame: 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in